With 3.0 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.35 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $8.3497 whereas the lowest price it dropped to was $7.605. The 52-week range on AVDL shows that it touched its highest point at $19.09 and its lowest point at $7.39 during that stretch. It currently has a 1-year price target of $18.64. Beta for the stock currently stands at 1.34.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AVDL was down-trending over the past week, with a drop of -29.29%, but this was down by -21.80% over a month. Three-month performance dropped to -39.66% while six-month performance fell -52.89%. The stock lost -47.81% in the past year, while it has lost -25.59% so far this year. A look at the trailing 12-month EPS for AVDL yields -0.77 with Next year EPS estimates of 0.15. For the next quarter, that number is -0.04. This implies an EPS growth rate of 75.00% for this year and 130.00% for next year.
Float and Shares Shorts:
At present, 96.34 million AVDL shares are outstanding with a float of 88.15 million shares on hand for trading. On 2024-12-31, short shares totaled 11.77 million, which was 1222.0000499999999 higher than short shares on 1732838400. In addition to Mr. Gregory J. Divis Jr. as the firm’s CEO & Director, Mr. Thomas S. McHugh serves as its Senior VP, Principal Financial and Accounting Officer & CFO.
Institutional Ownership:
Through their ownership of 0.80547 of AVDL’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, AVDL reported revenue of $50025000.0 and operating income of -$327000.0. The EBITDA in the recently reported quarter was $708000.0 and diluted EPS was -$0.03.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AVDL since 8 analysts follow the stock currently. There are 8 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AVDL analysts setting a high price target of 22.0 and a low target of 13.0, the average target price over the next 12 months is 18.4. Based on these targets, AVDL could surge 181.33% to reach the target high and rise by 66.24% to reach the target low. Reaching the average price target will result in a growth of 135.29% from current levels.
Analysts have provided yearly estimates in a range of -$0.45459 being high and -$0.54551 being low. For AVDL, this leads to a yearly average estimate of -$0.495. Based on analyst estimates, the high estimate for the next quarter is -$0.02 and the low estimate is -$0.07. The average estimate for the next quarter is thus -$0.04.
